Navigation Links
Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project, Upcoming Webinar Hosted by Xtalks
Date:11/11/2019

Immunotherapies are currently the most rapidly growing drug class and have a major impact in the oncology field. While these approaches have demonstrated impressive results for some patients, important challenges still need to be overcome. Among these, defining valuable and adapted combination protocols, predicting responders to therapies through biomarkers, follow-up or overcoming resistance development to current immunotherapies are major goals to achieve.

The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.

On Wednesday, November 27, 2019 at 11am EST (4pm GMT/UK), join a live webinar where Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Next, Professor Fabrice Barlesi, Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, will focus on the choice of relevant immune-related biomarkers to be tested in order to predict and overcome resistance to treatments in patients suffering from lung cancer. The Pioneer Project, supported by the French Research Agency, will illustrate this topic.

This webinar will also include a brief overview of a powerful immuno-oncology platform that can provide meaningful and actionable data through biomarker testing.

For more information or to register for this event, visit Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Read the full story at https://www.prweb.com/releases/evaluating_biomarkers_during_clinical_trials_for_immunotherapies_a_case_study_on_the_pioneer_project_upcoming_webinar_hosted_by_xtalks/prweb16710081.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. New JAMA Report, Initiated by AAAAI and Others, Provides Recommendations for Evaluating and Managing Penicillin Allergy
2. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
3. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinsons Disease
4. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
5. Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy
6. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
7. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma
8. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
9. AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
10. Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models
11. Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2020)... ... 2020 , ... MCH has been tracking trends and compiling contact and demographic ... comprehensive database of district and school institution, personnel, enrollment and program data to ... The COVID-19 impact map and related data can be used by anyone as outlined ...
(Date:3/16/2020)... STERLING, Va. (PRWEB) , ... March 16, 2020 , ... ... fun activities, we take our social responsibility very seriously,” states CEO Steven L. Yeffa. ... close all our locations as of March 16, 2020 in an effort to prevent ...
(Date:3/15/2020)... BELMONT, N.C. (PRWEB) , ... March 14, 2020 ... ... home has some seniors scared -- not only of infection, but increased isolation. ... via our software platform, so the right message gets to the right person ...
Breaking Medicine Technology:
(Date:3/22/2020)... ... ... In partnership with UC Health, Cincy Shirts has created a new t-shirt design entitled ... comes from the English translation of “Juncta Juvant”, the City of Cincinnati’s motto found ... sale of the shirt will benefit the YMCA of Cincinnati Emergency Response Fund that ...
(Date:3/20/2020)... ... ... CommunityMed Urgent Care , based in Dallas, has rolled out a ... present online, complete registration paperwork (including the latest COVID screening) provide IDs and insurance ... that their clean exam room is ready. All of this is done via ...
(Date:3/19/2020)... ... March 19, 2020 , ... ... to teach Executive Function, shares a free Student Learning Exercise: ExQ® Superpower ... parents and teachers are seeking resources to help with the immediate need for ...
(Date:3/16/2020)... ... March 16, 2020 , ... The National Kidney ... Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR’s vast network of ... serves approximately 100 transplant programs throughout the United States. NKR has relied on ...
(Date:3/15/2020)... Idaho (PRWEB) , ... March ... ... uncertainty and rising levels of confusing information surrounding the Coronavirus (COVID-19) pandemic, ... bear on the health concerns of businesses and employees. HouseCheck has launched ...
Breaking Medicine News(10 mins):